// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

ScanNav® Audit: an AI-powered screening assistant for fetal anatomical ultrasound

Mohammad Yaqub - Society for Maternal-Fetal Medicine (SMFM) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Evaluation of hyaluronic acid as a possible biomarker in rat models of preeclampsia

Sarah K. Shea - Society for Maternal-Fetal Medicine (SMFM) , 2021

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Preeclampsia

Hyaluronic acid

Clinical Outcome at 6th Month Between Paclitaxel Coated Balloon Versus Sirolimus Coated Balloon in De-Novo Coronary Lesions

Sandeep Basavarajaiah - Angioplasty Summit-TCTAP , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

Paclitaxel

Ain Shams University Experience in Different Methods of Percutaneous Extraction of Pacemaker and Defibrillation Leads

Hassan Shehata Hassan El dawy - Angioplasty Summit-TCTAP , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Polymer Free Drug-Eluting Stents Versus Durable Polymer Drug-Eluting Stents in Elective Percutaneous Coronary Interventions in Patients with Stable Coronary Artery Disease Patients

Sherif Mohammad Aziz Altoukhy - Angioplasty Summit-TCTAP , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Stable coronary artery disease

N/A

Neuronal effects of music entrainment versus preferred music in three patients with chronic cancer pain as measured via EEG and LORETA imaging

Andrea Hunt - Pain Week Conference , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic pain

N/A

Consensus Recommendations on Dosing and Administration of Medical Cannabis to Treat Chronic Pain: Results of a Modified Delphi Process

Arun Bhaskar - Pain Week Conference , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Chronic pain

N/A

10 kHz Spinal Cord Stimulation for Treatment of Painful Diabetic Neuropathy – A Multicenter Randomized Controlled Trial

Erika Petersen - Pain Week Conference , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic neuropathy

Morphine

The use of external neuromodulation in a community chronic pain service

Johanna Theron - Pain Week Conference , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Chronic pain

Midotens

Ketamine metabolites in the treatment of neuropathic pain

Lucas Stolle - Pain Week Conference , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Pain (neuropathic)

norketamine

Concern about addiction is associated with lower quality of life in patients with osteoarthritis: an observational data analysis

Louis P Garrison Jr - Pain Week Conference , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

Methadone hydrochloride

Treatment patterns of patients with moderate-to-severe osteoarthritis in the United States

Ryan Hansen - Pain Week Conference , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Osteoarthritis

N/A

The impact of pain severity on treatment patterns, adherence and healthcare resource utilization among individuals with osteoarthritis in the United States.

Patricia Schepman - Pain Week Conference , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Osteoarthritis

N/A

Ubrogepant is effective in the acute treatment of migraine with mild pain

Richard Lipton - Pain Week Conference , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Migraine

Ubrogepant

Prescribing NSAIDs/COX-2s in patients having osteoarthritis is associated with both negative clinical outcomes and higher costs

Stuart Silverman - Pain Week Conference , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Osteoarthritis

N/A

Peripherally induced reconditioning of the central nervous system: proposed mechanisms for sustained relief of chronic pain with percutaneous peripheral nerve stimulation

Timothy Deer - Pain Week Conference , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Chronic pain

N/A

Tobacco exposure and somatic mutations in normal bronchial epithelia

Kenichi Yoshida - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Oral cancer

N/A

Development of first-in-class small molecule inhibitors of FLIP which activate caspase-8, the nodal regulator of apoptosis, necroptosis and pyroptosis

Daniel B. Longley - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

selumetinib

NF-kB associates with tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Andres J. Rubio - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Tocilizumab

Effect of co-mutations and FLT3-ITD variant allele frequency (VAF) on response to quizartinib or salvage chemotherapy (SC) in relapsed/refractory (R/R) acute myeloid leukemia (AML)

Alexander E. Perl - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

quizartinib

Copyright © 2026. QuantiNova All rights reserved